PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-13.21%
Cash & equivalents declining -13.21% while Biotechnology shows -12.44% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-13.21%
Cash + STI yoy growth 1.25-1.5x the Biotechnology median of -10.82%. Mohnish Pabrai might see a strategic surplus if short-term returns make sense.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.76%
Exceeding 1.5x Biotechnology median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-11.17%
1.25-1.5x the Biotechnology median of -9.74%. Mohnish Pabrai would examine if this advantage is strategic or idle cash buildup.
7.73%
PP&E growth below half of Biotechnology median of -2.90%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Below half Biotechnology median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.08%
Below half the Biotechnology median of -1.66%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
-10.65%
1.25-1.5x Biotechnology median of -7.40%. Mohnish Pabrai might see above-average growth. Check if financed sensibly.
-100.00%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Below half Biotechnology median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
1577.51%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-26.01%
Above 1.5x Biotechnology median of -4.12%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
No Data
No Data available this quarter, please select a different quarter.
-0.35%
Below half Biotechnology median of -2.49%. Joel Greenblatt sees more conservative long-term liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-6.06%
Above 1.5x Biotechnology median of -2.47%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
-3.82%
0.5-0.75x Biotechnology median of -5.30%. Guy Spier is cautious about weaker retention vs. peers.
100.00%
Above 1.5x Biotechnology median 1.52%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
-13.95%
≥ 1.5x Biotechnology median of -8.37%. Joel Greenblatt sees stronger equity growth vs. peers.
-10.65%
1.25-1.5x Biotechnology median of -7.45%. Mohnish Pabrai notes above-average growth in liabilities + equity.
-100.00%
Below half Biotechnology median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-4.69%
Above 1.5x Biotechnology median of -1.30%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
13.42%
Near Biotechnology median 13.50%. Charlie Munger sees typical yoy changes in net debt among the sector.